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Introduction
Development of breast cancer is a multiple process involving an interplay between genetic and environmental factors, including diets and hormones. Breast cancer mortality remains the second leading cause of cancer deaths in women among western countries (1) . Recently, several epidemiological studies have suggested that there is an inverse association between Abbreviations: AgNOR, silver-stained nucleolar organizer region protein; COX, cyclooxygenase; ISEL, in situ end-labeling of fragmented DNA; NSAID, non-steroidal anti-inflammatory drug; PG, prostaglandin; PhIP, 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine; RT-PCR, reverse transcription-polymerase chain reaction; SD, Sprague-Dawley. the risk of breast cancer and intake of non-steroidal antiinflammatory drugs (NSAIDs) (2, 3) , which block the prostaglandin (PG) cascade by inhibition of its rate-limiting enzyme, cyclooxygenase (COX). There are two isoforms, COX-1 and COX-2. Accumulating evidence indicates that COX-2, which is inducible and contributes to pathological processes such as inflammation and abnormal cell proliferation, plays a pivotal role in mammary gland (4) and colon (5) cancer development. Several selective inhibitors have in fact already demonstrated inhibitory effects on mammary gland (6, 7) and colon (8, 9) carcinogenesis in rodent models. In human breast cancers, elevated levels of COX-2 and PGE 2 have been widely reported (10) (11) (12) (13) . Furthermore, levels of COX-2 and PGE 2 were elevated in rodent mammary gland tumors (7, 14) . PGE 2 exhibits biological activity through binding to membrane receptors, EP [1] [2] [3] [4] . It was suggested that potential of breast cancer development and metastasis are related to PGE function through its receptors before being identified (15, 16) . Recently, Zhao et al. (17) indicated that PGE 2 stimulates the promoter II region of the cytochrome P-450 aromatase gene (CYP 19) through binding to its receptors, EP 1 and EP 2 . Taken together, it is suggested that PGE 2 plays important roles related to estrogen biosynthesis in mammary gland carcinogenesis through its receptors. Thus, we postulated that blockage of PGE receptors resulting in suppression of PGE function should inhibit mammary gland carcinogenesis. ONO-8711, a newly synthesized selective PGE receptor EP 1 antagonist, was introduced as a candidate of chemopreventive agents against colon carcinogenesis in our previous study (18) , inhibiting the development of azoxymethane-induced colonic aberrant crypt foci, putative preneoplastic lesions, in mice and intestinal polyp formation in Min mice, which overexpress COX-2 protein. In addition, our previous study indicated that mammary gland cancers induced by 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP) in female SpragueDawley (SD) rats reveal upregulation of COX-2 protein compared with normal mammary gland tissues (7) . PhIP is one of the well-known heterocyclic amines, which are thought to be the important dietary factors in breast cancer development by accumulating evidence from some animal and human studies (19, 20) . Recently, Sinha et al. identified PhIP as the most important heterocyclic amines in cooked meat for breast cancer development (21) . As using PhIP as a carcinogen to develop breast cancers is similar to the situations of human breast cancer development, we employed PhIP and SD female rats. The present study was designed to investigate the effects of ONO-8711 on PhIP-induced mammary gland carcinogenesis and expression status of EP 1 receptor in normal and cancer tissues of mammary gland in female SD rats. Moreover, the effects of this compound on cell proliferation and apoptosis in mammary gland cancer cells were examined. Our final goal is to determine whether ONO-8711 is an effective chemopreventive agent in preclinical efficacy studies so that, eventually, it may be assessed in human clinical trials. 
Materials and methods

Chemicals and animals
PhIP-HCl was purchased from the Nard Institute (Osaka, Japan). The selective EP 1 
-hexenoic acid} was chemically synthesized at Ono Pharmaceutical Co., Ltd. Its structure is shown in Figure 1 . ONO-8711 acts as a competitive antagonist at EP 1 receptors: it inhibits PGE 2 -induced increase in cytosolic Ca 2ϩ concentration with IC 50 of 0.21, 0.05, and 0.22 µM for the mouse, human, and rat receptors, respectively. Weanling female SD rats and all ingredients of the semipurified diets were purchased from CLEA Japan Inc. (Tokyo, Japan). The composition of the high polyunsaturated fat diet used in this study was as detailed in our previous study (22) . Experimental diets were prepared by adding ONO-8711 at 0.04 and 0.08% and stored in a cold room. Diet was provided to rats once a week. During the study, dietary ONO-8711 was confirmed to be stable.
Experimental procedure At 7 weeks of age, all rats except those intended for vehicle (saline) treatment received PhIP (85 mg/kg body weight) by gavage four times weekly for 2 weeks. Rats treated with PhIP were divided into three groups fed the control or experimental diets including 400 or 800 p.p.m. ONO-8711. Those receiving the vehicle were divided into two groups given the control or the experimental diet with ONO-8711 at 800 p.p.m. All animals had ad libitum access to diets and tap water during the study. They were monitored daily for their general health and mammary tumor development. The experiment was terminated 20 weeks after the last dosing of PhIP, all animals being killed under ether euthanasia. At complete autopsy, the numbers and sizes of all mammary tumors were recorded. The length (L), width (W) and depth (D) of each lesion were measured with calipers and tumor volume (V) was calculated using the formula VϭL•W•Dπ/6 (23). Half of each tumor was fixed with 10% neutral buffered formalin for evaluation of histopathological diagnosis and the remainder was frozen for subsequent biochemical analyses. For histopathological examination, formalin-fixed tumors were embedded in paraffin and 5 µm sections were prepared and stained with hematoxylin and eosin. Pathological diagnosis of mammary gland tumors was made principally based on the classification of Russo et al. (24) . Invasive ductal carcinomas were diagnosed as mammary gland tumors with invasion to surrounding tissues.
Analyses for cell proliferation and apoptosis
Deparaffinized sections underwent silver-stained nucleolar organizer region protein (AgNOR) staining according to Ploton et al. (25) to assess cell proliferation. Briefly, the colloid silver solution for staining the NORs was prepared by dissolving gelatin in 1% aqueous formic acid at concentration of 2%. This solution was mixed with 60% aqueous silver nitrate as the working solution, in which sections were incubated for 60 min at room temperature, protected from sunlight, then washed with deionized water. Careful focusing allowed AgNOR to be visualized in nuclei as black dots under a microscope. For measurement, three photographs of each lesion, at a final magnification of ϫ400, were prepared and 500 to 750 tumor cells in each photograph were analyzed. Other sections were stained with in situ end-labeling of fragmented DNA (ISEL) using ApopTag in situ detection peroxidase kit (Intergen Co., Purchase, NY) according to the manufacturer's instructions. For analysis of apoptosis, only well-defined and darkly stained cells and bodies were counted using a microscope. At least three areas of each lesion, 500 tumor cells in each area, were analyzed to generate an apoptotic index expressed as the percentage of apoptotic cells. manufacturer's instructions. Reverse transcription with random 9 mers was used to generate cDNAs from 0.8 µg of total RNA extracts using reverse transcriptase (AMV Reverse Transcriptase XL) and a Takara RNA LA PCR kit (Takara Biomedical Co. Inc., Japan). The following primers were used for PCR amplification of the resulting cDNA (PCR conditions were 94°C for 120 s and then 30 cycles of 98°C for 5 s, 60°C for 30 s, and 72°C for 30 s): EP 1 (256 bp) forward primer 5Ј-TAACGGCACATCACCAGCG-3Ј (nucleotides 684-702), and reverse primer 5Ј-GCAGCCGCCC AGG-AAATG-3Ј (nucleotides 922-939) (26); β-actin (203 bp) forward primer 5Ј-TCCTCCCTGGAGAAGAGCTA-3Ј (nucleotides 741-760), and reverse primer 5Ј-CCAGACAGCACTGTGTTGGC-3Ј (nucleotides 924-943) (27) .
PCR detection of EP
Statistical analysis
Body weight, tumor incidence, tumor multiplicity, and volume data, as well as AgNORs count/nucleus, and apoptotic indices were compared between the animals fed the control and ONO-8711 diets. Tumor incidence, expressed as the percentage of tumor-bearing animals, was analyzed by Fisher's exact probability test, whereas tumor multiplicity, expressed as the mean number of tumors per animal, and the other variables were analyzed by the unpaired Welch's t-test. Differences were considered statistically significant at P Ͻ 0.05.
Results and discussion
The body weights of animals throughout the study are indicated in Figure 2A . As expected, body weights of rats treated with saline were higher than those in rats treated with PhIP, but no body weight retardation was evident with ONO-8711 feeding. No toxic symptoms were observed in rats fed ONO-8711 at both doses during the study. Figure 2B and C indicate time course of changes in incidence and multiplicity of palpable breast tumors, respectively, during Chemoprevention of breast cancer the study. At 8 weeks after the last dosing of PhIP, first palpable breast tumors were noticed in rats treated with PhIP and fed the control diet. In rats fed ONO-8711 at 400 or 800 p.p.m., first palpable breast tumors were found at 10 or 12 weeks after the last PhIP treatment, respectively. Thus, administration of ONO-8711 at 400 or 800 p.p.m. delayed occurrence of breast tumors for 2 or 4 weeks, respectively. Incidences of palpable breast tumors in rats treated with PhIP and fed the control diet were slightly higher than in their counterparts receiving the experimental diets, but the difference lacked statistical significance. Multiplicity of palpable breast tumors in rats fed ONO-8711 at 800 p.p.m. was lower than that in rats fed the control diet throughout the study; significant differences between them after 19 weeks were identified. In both incidence and multiplicity of palpable breast tumors, there were no differences between ONO-8711 at 400 p.p.m. and the control diet groups. No breast tumors were observed in rats treated without PhIP initiation during the study. At 20 weeks after the last dosing of PhIP, all animals were killed and complete autopsy was performed. Rats treated with saline and fed ONO-8711 at 800 p.p.m. did not produce any gross or histological changes in mammary glands, liver, lungs, kidneys, stomach, or intestines which would indicate toxicity. No neoplastic lesions other than breast tumors were found in rats treated with PhIP and fed the control or ONO-8711 at both doses. Histopathological examination revealed all mammary gland tumors induced by PhIP to be diagnosed as invasive ductal carcinomas. Table I summarizes the final data for breast cancers induced by PhIP. In the ONO-8711 at 400 and 800 p.p.m. feeding groups, 62% (18/29) and 56% (18/32) of rats developed breast cancers, respectively, whereas the figure was 79% (26/33) for the controls. ONO-8711 at 800 p.p.m. feeding significantly suppressed cancer incidence compared with the control diet group (56% versus 79%, P Ͻ 0.05). Moreover, administration of ONO-8711 at 800 p.p.m. significantly decreased cancer multiplicity (2.5 versus 1.2, P Ͻ 0.05) as well as breast cancer volume (0.7 versus 1.4 cm 3 , P Ͻ 0.01). ONO-8711 at 400 p.p.m. feeding decreased cancer incidence, however, the difference was not statistically significant. The lack of an inhibitory effect of ONO-8711 at 400 p.p.m. may indicate that higher blood levels of this agent are required to achieve adequate mammary gland exposure.
To elucidate the mechanisms of inhibition by ONO-8711 on PhIP-induced breast cancer development, cell proliferation and apoptotic index were investigated (Table II) . Neither dose of ONO-8711 showed any effects on AgNORs count/nucleus in breast cancers. However, the apoptotic index in cancers was significantly elevated by administration of ONO-8711 at (28) . By using ISEL on tissue sections, early stages of apoptosis, not detectable by routine H&E stains, can be identified (29) . The net growth rate of a tumor mass reflects the balance of cell gain and loss and in the present study appeared to exert its effects mainly on the latter. Using RT-PCR method, EP 1 receptor was detected in breast cancers, not in the normal tissues ( Figure 3 ). These bands were confirmed EP 1 receptors by sequencing (data not shown). To our knowledge, this is the first report that rat breast cancers express the EP 1 receptor and the results point to a physiological importance. The expression of EP 1 receptor may be crucial to progress mammary gland carcinogenesis, and ONO-8711 blocks EP 1 receptor resulting in inhibition of breast cancer development. In PhIP-induced breast cancers, COX-2 protein was overexpressed (7) and that may contribute to overload of PGE 2 . COX-2 and PGE 2 are closely associated with estrogen biosynthesis through aromatase gene (CYP 19) and these three members may be involved in mammary gland carcinogenesis through EP 1 receptor. Recently, Liu et al. (30) reported that enhanced COX-2 expression is sufficient to induce mammary gland tumorigenesis. COX-2 can act as an oncogene under certain circumstances, leading to the production of PGE 2 which could then act in an autocrine or paracrine way to induce signaling via EP receptors, at least EP 1 receptor.
In conclusion, ONO-8711, a selective PGE receptor EP 1 antagonist, significantly inhibited breast cancer development, presumably through the induction of apoptosis. Also, we found EP 1 receptor expression in PhIP-induced breast cancers, but not in normal tissues. Moreover, it is noteworthy that ONO-8711 at 800 p.p.m. did not induce any symptoms of toxicity. These findings suggest that EP 1 receptor expression is involved in mammary gland carcinogenesis and EP 1 receptor antagonists may possess chemopreventive activity through the induction of apoptosis.
